Customization: | Available |
---|---|
CAS No.: | 137862-53-4 |
Formula: | C24h29n5o3 |
Still deciding? Get samples of US$ 1/kg
Request Sample
|
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Product name | Factory Supply Sacubitril Valsar 1038924-70-7 buy Sacubitril Valsartan |
Appearance | White powder |
Molecular formula | C48h58n6o8 |
Keywords | Sacubitril Valsartan ,1038924-70-7 Sacubitril Valsartan,LCZ696 |
Shelf Life | 24 months when properly stored |
Storage | Keep in a cool, dry, dark location |
LCZ696 a drug developed by Novartis Pharmaceutical of the United States for the treatment of heart failure. Heart failure is a life-threatening disease. The patient's heart cannot pump enough blood to supply the body, and appear the symptoms of dyspnea, fatigue and fluid retention slowly, then gradually increased, significantly affect the quality of life.
LCZ696 is a dual-acting angiotensin-receptor enkephalinase inhibitor that has a unique mechanism that is thought to reduce the strain of failing hearts. LCZ696 can enhance the body's natural defense against heart failure, as well as increase the level of natriuretic peptides and other endogenous vasoactive peptides, and inhibit the renin-angiotensin-aldosterone system (RAAS). LCZ696 has combined with Novartis's Hypertension Medication (Diovan, generic name: valsartan) and the experimental drug AHU-377. AHU377 blocks the mechanism of the two peptides responsible for lowering blood pressure. Diovan improves vasodilatation and stimulates the body to excrete sodium and water.
The safety threshold of cardiovascular drugs is extremely high, and LCZ696 even shows a higher safety than conventional drugs. Previously, Novartis vigorously develop the cardiovascular drug- serelaxi, while because of security issues, both the FDA and the European Union did
What is Sacubitril Valsartan
LCZ696 is a dual angiotensin II receptor antagonist and neprilysin inhibitor that is a combination of the nonpeptide angiotensin II receptor antagonist valsartan (Item No. 14178) and AHU377 (Item No. 21473), a prodrug of LBQ657 (Item No. 19829), which is an inhibitor of the zinc metallopeptidase neprilysin., LCZ696 (2-60 mg) induces a dose-dependent decrease in mean arterial pressure in rats expressing human renin and angiotensinogen, a double-transgenic model for angiotensin II-dependent hypertension. Formulations containing LCZ696 are under clinical investigation for the treatment of mild to moderate hypertension and chronic heart failure.
Packing and delivering
Certification